Multi-billion dollar vote of confidence in UK protein specialist

Multi-billion dollar vote of confidence in UK protein specialist
5 May 2022
The Pharma Letter – View full story

Dundee’s Amphista strikes collaboration deals that could be worth billions

Dundee’s Amphista strikes collaboration deals that could be worth billions
5 May 2022
The Herald Scotland – View full story

Amphista Therapeutics signs with pharma on drug development projects

Amphista Therapeutics signs with pharma on drug development projects
5 May 2022
Drug Discovery World – View full story

Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform

Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform
5 May 2022
PharmaShots – View full story

Amphista Therapeutics to Collaborate with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

Amphista Therapeutics to Collaborate with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
4 May 2022
American Pharmaceutical Review – View full story

Amphista announces collaborations potentially worth $2 billion

Amphista announces collaborations potentially worth $2 billion
4 May 2022
Bio-dundee – View full story

BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform

BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform
4 May 2022
PharmaLive – View full story
Reprint of BioSpace article

Bristol Myers Squibb (BMY) Announces Amphista Therapeutics Collaboration

Bristol Myers Squibb (BMY) Announces Amphista Therapeutics Collaboration
4 May 2022
InvestorsObserver – View full story

Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics

Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
4 May 2022
Pipeline Review – View full story

Amphista lands potentially rich deals with Merck, BMS

Amphista lands potentially rich deals with Merck, BMS
4 May 2022
BioWorld – View full story